Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther February 1 2014 13 (2) 273-273;

Review

  • Review
    Targeting Microtubules by Natural Agents for Cancer Therapy
    Eiman Mukhtar, Vaqar Mustafa Adhami and Hasan Mukhtar
    Mol Cancer Ther February 1 2014 13 (2) 275-284; DOI:10.1158/1535-7163.MCT-13-0791

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer
    Krishnendu Pal, Ying Cao, Irina N. Gaisina, Santanu Bhattacharya, Shamit K. Dutta, Enfeng Wang, Hendra Gunosewoyo, Alan P. Kozikowski, Daniel D. Billadeau and Debabrata Mukhopadhyay
    Mol Cancer Ther February 1 2014 13 (2) 285-296; DOI:10.1158/1535-7163.MCT-13-0681

  • Small Molecule Therapeutics
    Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines
    Marie R. Webster, Chandrashekhar Kamat, Nick Connis, Ming Zhao, Ashani T. Weeraratna, Michelle A. Rudek, Christine L. Hann and Caren L. Freel Meyers
    Mol Cancer Ther February 1 2014 13 (2) 297-306; DOI:10.1158/1535-7163.MCT-13-0315

  • Small Molecule Therapeutics
    Selective Inhibition of Pancreatic Ductal Adenocarcinoma Cell Growth by the Mitotic MPS1 Kinase Inhibitor NMS-P715
    Roger B. Slee, Brenda R. Grimes, Ruchi Bansal, Jesse Gore, Corinne Blackburn, Lyndsey Brown, Rachel Gasaway, Jaesik Jeong, Jose Victorino, Keith L. March, Riccardo Colombo, Brittney-Shea Herbert and Murray Korc
    Mol Cancer Ther February 1 2014 13 (2) 307-315; DOI:10.1158/1535-7163.MCT-13-0324

  • Small Molecule Therapeutics
    Inhibition of Insulin-like Growth Factor–Binding Protein-3 Signaling through Sphingosine Kinase-1 Sensitizes Triple-Negative Breast Cancer Cells to EGF Receptor Blockade
    Janet L. Martin, Hasanthi C. de Silva, Mike Z. Lin, Carolyn D. Scott and Robert C. Baxter
    Mol Cancer Ther February 1 2014 13 (2) 316-328; DOI:10.1158/1535-7163.MCT-13-0367

  • Small Molecule Therapeutics
    The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
    Masamichi Mori, Yoko Ueno, Satoshi Konagai, Hiroshi Fushiki, Itsuro Shimada, Yutaka Kondoh, Rika Saito, Kenichi Mori, Nobuaki Shindou, Takatoshi Soga, Hideki Sakagami, Takashi Furutani, Hitoshi Doihara, Masafumi Kudoh and Sadao Kuromitsu
    Mol Cancer Ther February 1 2014 13 (2) 329-340; DOI:10.1158/1535-7163.MCT-13-0395

  • Small Molecule Therapeutics
    A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
    Karishma S. Amin, Shankar Jagadeesh, Gakul Baishya, Paruchuri G. Rao, Nabin C. Barua, Samir Bhattacharya and Partha P. Banerjee
    Mol Cancer Ther February 1 2014 13 (2) 341-352; DOI:10.1158/1535-7163.MCT-13-0478

  • Small Molecule Therapeutics | AuthorChoice
    Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
    Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira, Suqin He, Jim Sang, Richard C. Bates and David A. Proia
    Mol Cancer Ther February 1 2014 13 (2) 353-363; DOI:10.1158/1535-7163.MCT-13-0481

  • Small Molecule Therapeutics
    Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
    Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, Harold B. Brooks, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Jeremy R. Graff, Enrique Jambrina, Mary Mader, Denis McCann, Songqing Na, Stephen H. Parsons, Susan E. Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Courtney Tate, Juan A. Velasco, Yong Wang and Xiang S. Ye
    Mol Cancer Ther February 1 2014 13 (2) 364-374; DOI:10.1158/1535-7163.MCT-13-0513

Large Molecule Therapeutics

  • Large Molecule Therapeutics
    Increasing the Antitumor Effect of an EpCAM-Targeting Fusion Toxin by Facile Click PEGylation
    Manuel Simon, Nikolas Stefan, Lubor Borsig, Andreas Plückthun and Uwe Zangemeister-Wittke
    Mol Cancer Ther February 1 2014 13 (2) 375-385; DOI:10.1158/1535-7163.MCT-13-0523

  • Large Molecule Therapeutics
    Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling
    Neil R. Michaud, Youzhen Wang, Kristen A. McEachern, Jerold J. Jordan, Anne Marie Mazzola, Axel Hernandez, Sanjoo Jalla, Jon W. Chesebrough, Mark J. Hynes, Matthew A. Belmonte, Lidong Wang, Jaspal S. Kang, Jelena Jovanović, Naomi Laing, David W. Jenkins, Elaine Hurt, Meina Liang, Christopher Frantz, Robert E. Hollingsworth, Diane M. Simeone, David C. Blakey and Vahe Bedian
    Mol Cancer Ther February 1 2014 13 (2) 386-398; DOI:10.1158/1535-7163.MCT-13-0420

  • Large Molecule Therapeutics | AuthorChoice
    Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
    Katrin Friedbichler, Marco H. Hofmann, Monika Kroez, Elinborg Ostermann, Herbert R. Lamche, Christian Koessl, Eric Borges, Michael N. Pollak, Günther Adolf and Paul J. Adam
    Mol Cancer Ther February 1 2014 13 (2) 399-409; DOI:10.1158/1535-7163.MCT-13-0598

  • Large Molecule Therapeutics | AuthorChoice
    MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
    Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia, Jian Tang, Victoria Rimkunas, Lihui Xu, Neeraj Kohli, Rachel Rennard, Maja Razlog, Yang Jiao, Brian D. Harms, Kenneth J. Olivier Jr, Birgit Schoeberl, Ulrik B. Nielsen and Alexey A. Lugovskoy
    Mol Cancer Ther February 1 2014 13 (2) 410-425; DOI:10.1158/1535-7163.MCT-13-0255

  • Large Molecule Therapeutics
    The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy
    Kohei Sano, Takahito Nakajima, Peter L. Choyke and Hisataka Kobayashi
    Mol Cancer Ther February 1 2014 13 (2) 426-432; DOI:10.1158/1535-7163.MCT-13-0633

Cancer Biology and Signal Transduction

  • Cancer Biology and Signal Transduction
    Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
    Junko Murai, Shar-Yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H. Doroshow and Yves Pommier
    Mol Cancer Ther February 1 2014 13 (2) 433-443; DOI:10.1158/1535-7163.MCT-13-0803

  • Cancer Biology and Signal Transduction
    MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
    Kazuhiro Kitamura, Masahiro Seike, Tetsuya Okano, Kuniko Matsuda, Akihiko Miyanaga, Hideaki Mizutani, Rintaro Noro, Yuji Minegishi, Kaoru Kubota and Akihiko Gemma
    Mol Cancer Ther February 1 2014 13 (2) 444-453; DOI:10.1158/1535-7163.MCT-13-0448

  • Cancer Biology and Signal Transduction
    GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
    David J. Duffy, Aleksandar Krstic, Thomas Schwarzl, Desmond G. Higgins and Walter Kolch
    Mol Cancer Ther February 1 2014 13 (2) 454-467; DOI:10.1158/1535-7163.MCT-13-0560-T

  • Cancer Biology and Signal Transduction | AuthorChoice
    Therapeutic Inhibition of Jak Activity Inhibits Progression of Gastrointestinal Tumors in Mice
    Emma Stuart, Michael Buchert, Tracy Putoczki, Stefan Thiem, Ryan Farid, Joachim Elzer, Dennis Huszar, Paul M. Waring, Toby J. Phesse and Matthias Ernst
    Mol Cancer Ther February 1 2014 13 (2) 468-474; DOI:10.1158/1535-7163.MCT-13-0583-T

  • Cancer Biology and Signal Transduction
    Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss
    Ellen M. Beauchamp, Brittany A. Woods, Austin M. Dulak, Li Tan, Chunxiao Xu, Nathanael S. Gray, Adam J. Bass, Kwok-kin Wong, Matthew Meyerson and Peter S. Hammerman
    Mol Cancer Ther February 1 2014 13 (2) 475-482; DOI:10.1158/1535-7163.MCT-13-0817

  • Cancer Biology and Signal Transduction
    Blocking SDF-1α/CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow–Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors
    Randala Hamdan, Zhichao Zhou and Eugenie S. Kleinerman
    Mol Cancer Ther February 1 2014 13 (2) 483-491; DOI:10.1158/1535-7163.MCT-13-0447

  • Cancer Biology and Signal Transduction
    OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice
    Dilek Iusuf, Marion Ludwig, Ahmed Elbatsh, Anita van Esch, Evita van de Steeg, Els Wagenaar, Martin van der Valk, Fan Lin, Olaf van Tellingen and Alfred H. Schinkel
    Mol Cancer Ther February 1 2014 13 (2) 492-503; DOI:10.1158/1535-7163.MCT-13-0541

  • Cancer Biology and Signal Transduction
    Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy
    Xi Chen, Elena Díaz-Rodríguez, Enrique M. Ocio, Bruno Paiva, Deborah S. Mortensen, Antonia Lopez-Girona, Rajesh Chopra, Jesús San Miguel and Atanasio Pandiella
    Mol Cancer Ther February 1 2014 13 (2) 504-516; DOI:10.1158/1535-7163.MCT-13-0022

Companion Diagnostics and Cancer Biomarkers

  • Companion Diagnostics and Cancer Biomarkers | AuthorChoice
    Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
    Yu Wang, Qi Yu, Xin He, Todd Romigh, Jessica Altemus and Charis Eng
    Mol Cancer Ther February 1 2014 13 (2) 517-527; DOI:10.1158/1535-7163.MCT-13-0655

  • Companion Diagnostics and Cancer Biomarkers
    Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
    Yan Ning, Armin Gerger, Wu Zhang, Diana L. Hanna, Dongyun Yang, Thomas Winder, Takeru Wakatsuki, Melissa J. Labonte, Sebastian Stintzing, Nico Volz, Yu Sunakawa, Stefan Stremitzer, Rita El-Khoueiry and Heinz-Josef Lenz
    Mol Cancer Ther February 1 2014 13 (2) 528-539; DOI:10.1158/1535-7163.MCT-13-0646

  • Companion Diagnostics and Cancer Biomarkers
    Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab
    Elaine Mai, Zhong Zheng, Youjun Chen, Jing Peng, Christophe Severin, Ellen Filvaroff, Mally Romero, William Mallet, Surinder Kaur, Thomas Gelzleichter, Ihsan Nijem, Mark Merchant and Judy C. Young
    Mol Cancer Ther February 1 2014 13 (2) 540-552; DOI:10.1158/1535-7163.MCT-13-0494

Correction

  • Correction
    Correction: Aerosol Delivery of Urocanic Acid–Modified Chitosan/Programmed Cell Death 4 Complex Regulated Apoptosis, Cell Cycle, and Angiogenesis in Lungs of K-ras Null Mice
    Mol Cancer Ther February 1 2014 13 (2) 553-553; DOI:10.1158/1535-7163.MCT-13-1057

Back to top
PreviousNext
Molecular Cancer Therapeutics: 13 (2)
February 2014
Volume 13, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
  • Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
  • MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
  • Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation

Jump to

  • Highlights
  • Review
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Cancer Biology and Signal Transduction
  • Companion Diagnostics and Cancer Biomarkers
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • SLFN11 Expression in Prostate Cancer
  • Single-cell RNA-seq to Uncover Metastatic Targets in PDAC
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • ARX788 Efficacy in HER2-low and T-DM1–resistant Cancers
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement